ESMO 2024 | Evaluating CTC enumeration & PSA measurements in prostate cancer
Andrew Armstrong, MD, Duke Cancer Institute, Durham, NC, discusses the future of xaluritamig, which was assessed in a dose exploration trial (NCT04221542). Circulating tumor cell (CTC) enumeration, which is FDA-approved, was shown to potentially complement PSA measurements. While most patients showed declines in both PSA and CTCs, some exhibited CTC reduction without corresponding PSA decline, suggesting that CTC monitoring may provide additional insights for therapeutic decision-making and drug development. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
